We’re excited to gather at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting in Toronto, Canada starting tomorrow, June 8th through June 11th, where we will present a poster highlighting preclinical GD2-SADA data. Swing by booth #1845 and let's chat about making a difference! Read our press release for more information: https://lnkd.in/eyH7kJ8i #SNMMI #SNMMI24 #Radiotherapy
Y-mAbs Therapeutics, Inc.’s Post
More Relevant Posts
-
Join Spectrum Dynamics at the SNMMI Therapeutic Conference in Baltimore's Inner Harbor. Learn how Spectrum Dynamics is Breaking Boundaries in Diagnostic Accuracy: VERITON-CT SPECT/CT 400 series sets new standards in sensitivity and resolution, empowering clinicians to make precise diagnoses. Discover how this advanced SPECT/CT imaging system is revolutionizing the field of nuclear medicine. #DiagnosticAccuracy #ImagingTechnology
-
-
#DidYouKnow in the 2010's, the emergence of radiotherapeutics using isotopes like Lu-177 marked a milestone shift in the nuclear medicine market, changing the importance of isotopes in healthcare? The radiotherapeutic market represented 20% of the total nuclear medicine market in 2019, up from 6% in 2013. Through continued investment and innovation, it is projected that radiotherapeutics will represent around 75% of the market by 2031, massively expanding the possibilities for personalized medical treatments!
-
-
CTS series(Clinical Theranostics Specialist) Share my readings and my thoughts. 6-week interval, it will be written in the guideline
We can do better than a fixed set of 6 cycles of LuPSMA at a 6-week time interval ! Great multicenter data of >100 patients from Germany with beautiful swimmer plots just published in The Journal of Nuclear Medicine - JNM. Treatment holidays and extended use of LuPSMA can prolong survival in some patients. Happy to open our phase 2 trials FLEX-MRT NCT06216249 and RE-LuPSMA NCT06288113 at UCLA Health with Novartis. #theranostics #PSMA #nuclearmedicine https://lnkd.in/ephE49-K Johannes Czernin Thomas Hope Louise Emmett Michael Hofman Society of Nuclear Medicine and Molecular Imaging (SNMMI)
-
-
First-in-Human Pb-212-PSMA–Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant #Prostatecancer. #research #radiotheranostics #radiopharmaceuticals #PSMA #pb212 The Journal of Nuclear Medicine - JNM
-
🇲🇽Nuclear Medicine Physician/Professor, 🚀Leader Entrepreneur,💼 Business promoter & 💡Scientific adviser. Focused on private sector Molecular Imaging and Nuclear Medicine in Mexico.
Imaging “make the grade”; like this man… certainly, I am in the way to do it in my field: clinical nuclear medicine & molecular imaging as a businessman amd entrepreneur. | The MedicinaNuclearMX collective are Mexican Nuclear Medicine Physicians promoting, expanding clinical use & doing business by private sector in Mexico. #nuclearmedicine #molecularimaging #theranostics #radionuclidetherapy #PETct
-
-
SPECT vs PET as Nuclear Medicine Imaging Mechanism In SPECT (Single Photon Emission Tomography), the emitted radiation already is a Gamma ray, which is then directly used to create the camera mages. SPECT cameras use collimators to help localizing with precision the direction of the incoming ray. In PET (Positron Emission Tomography), the emitted radiation is a positron which,when interacting with the tissues around the radiopharmaceutical, creates 2 rays, one opposite the other. The rays hit a camera and the two signals taken in coincidence allow aprecise localization of the emission point.
-
-
Back to basics illustration of the nuc cameras 📷
SPECT vs PET as Nuclear Medicine Imaging Mechanism In SPECT (Single Photon Emission Tomography), the emitted radiation already is a Gamma ray, which is then directly used to create the camera mages. SPECT cameras use collimators to help localizing with precision the direction of the incoming ray. In PET (Positron Emission Tomography), the emitted radiation is a positron which,when interacting with the tissues around the radiopharmaceutical, creates 2 rays, one opposite the other. The rays hit a camera and the two signals taken in coincidence allow aprecise localization of the emission point.
-
-
As providers of technologies that support the accurate delivery, detection and diagnosis in nuclear medicine and molecular imaging, we support the Mirion Medical commitment to enhance safety at every stage of care. #WorldPatientSafetyDay
-
💡Application in the spotlight! In this study by Sankaranarayanan et al., Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, a theranostic approach was investigated in a TNBC xenograft mouse model by radiolabelling a close derivative of a PARPi Olaparib (termed PARPi-01) with the Auger emitters 123/125I. The γ-cube (SPECT) and X-cube (CT) were used for longitudinal follow-up and evaluation of the biodistribution of [123I]PARPi-01 four h and 24h post-injection. 🔗 Link to the application can be found in the comments! #PreclinicalImaging #PreclinicalResearch #SPECT
-
-
🇲🇽Nuclear Medicine Physician/Professor, 🚀Leader Entrepreneur,💼 Business promoter & 💡Scientific adviser. Focused on private sector Molecular Imaging and Nuclear Medicine in Mexico.
Good times are coming for nuclear medicine and molecular imaging! In the world tomorrow, there will be greater incorporation of these wonders of modern medical technology. 🙌🏼⭐️🇲🇽🚀 In Mexico and the world, we will need really NucMed physicians promoters committed with effective clinical implementation (not just clumsy academicals)| The MedicinaNuclearMX collective are Mexican Nuclear Medicine Physicians promoting, expanding clinical use & doing disruptive business by private sector in Mexico. #nuclearmedicine #molecularimaging #PETct #radionuclidetherapy #theranostics Data from MEDraysintell
-
